About Us Product Center Investor Relations News & Media Contact Us ENGLISH STOCK CODE: 00512.HK Grand Journey for A Healthier World GP (HK) Announces 2021 interim Results The total profit for the period attributable to owners of the Company amounted to approximately HK$1,202.5 million with an increment of approximately 67.4% as compared with the corresponding period in 2020. READ MORE Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud READ MORE Contact Us Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong ir@chinagrandpharm.com www.grandpharm.com Pages Links Company Profile Product Center Investor Relations News & Media Stock Info Contact Us Privacy Legal Statement Recent News GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China, Deepen the Dual-Cycle Development Strategy and Continues the Global Development Process 2021-11-10 GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT 2021-10-21 © 2021. 遠大醫藥集團有限公司 All Rights Reserved.

About Us Product Center Investor Relations News & Media Contact Us ENGLISH STOCK CODE: 00512.HK GP (HK) Announces 2021 interim Results The total profit for the period attributable to owners of the Company amounted to approximately HK$1,202.5 million with an increment of approximately 67.4% as compared with the corresponding period in 2020. READ MORE Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud READ MORE Contact Us Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong ir@chinagrandpharm.com www.grandpharm.com Pages Links Company Profile Product Center Investor Relations News & Media Stock Info Contact Us Privacy Legal Statement Recent News GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China, Deepen the Dual-Cycle Development Strategy and Continues the Global Development Process 2021-11-10 GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT 2021-10-21 © 2021. 遠大醫藥集團有限公司 All Rights Reserved.